Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29240417 | 1.00 | STING1 (1.00) | STING1CYP3A4 | |
| SCHEMBL29240487 | 0.97 | STING1 (0.95) | STING1CYP3A4 | |
| SCHEMBL30469456 | 0.97 | STING1 (0.95) | STING1CYP3A4 | |
| SCHEMBL21790381 | 0.91 | STING1 (0.84) | STING1CYP3A4 | |
| SCHEMBL21789787 | 0.91 | STING1 (0.88) | STING1 | |
| SCHEMBL30469461 | 0.89 | STING1 (0.82) | STING1 | |
| SCHEMBL19437693 | 0.88 | STING1 (0.82) | STING1 | |
| SCHEMBL30469470 | 0.88 | STING1 (0.81) | STING1 | |
| SCHEMBL30947787 | 0.87 | STING1 (1.00) | STING1CYP3A4 | |
| SCHEMBL29240412 | 0.87 | STING1 (1.00) | STING1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417486-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4412660-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118265545-A | Asymmetric bisbenzimidazole STING agonist immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023059544-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417486-A1 | ASYMMETRIC BIS-BENZIMIDAZOLE STING AGONIST IMMUNOCONJUGATES AND USES THEREOF | STING1, BID, MAVS | STING1 1/4885CYP3A4 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.